Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma - Concepedia

Concepedia

Publication | Open Access

Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

DOI Full Paper Access

143

Citations

28

References

2019

Year

Owen A. O’Connor, Muhıt Özcan, Eric D. Jacobsen, Josep M. Roncero, Judith Trotman, Judit Demeter, Tamás Masszi, Juliana Pereira, Radhakrishnan Ramchandren, Anne Beaven,

Journal of Clinical Oncology

Abstract

In patients with relapsed/refractory PTCL, alisertib was not statistically significantly superior to the comparator arm.

References

	Year	Citations

Page 1